UK's NICE Recommends Use of Genomic Health's OncoType DX in Draft Guidance
February 19, 2013
UK's NICE Recommends Use of Genomic Health's OncoType DX in Draft Guidance
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Genomic Health's Q1 Revenues Climb 17 Percent, Net Loss Turns to Profit
May 3, 2012 / GenomeWeb Daily News - Medicare to Cover Genomic Health's Oncotype DX Breast Cancer Test for DCIS
May 13, 2013 / GenomeWeb Daily News - Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter - FDA Clears ASI Gene Scanner as PGx Tool for NSCLC
February 15, 2013 / GenomeWeb Daily News - Genotox Labs Announced as First Customer for Translational Software’s PGx Interpretation, Integration Service
February 13, 2013 / Pharmacogenomics Reporter